News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

bioRASI to Exhibit at the ASCPT 2009 Annual Meeting in Washington, D.C.

3/17/2009 12:51:30 PM

HOLLYWOOD, FL--(Marketwire - March 16, 2009) -

bioRASI, a full service, global Contract Research Organization (CRO), announced today that they will participate in the ASCPT 2009 Annual Meeting in Washington, D.C., on March 18th - 21st. bioRASI will be exhibiting at booth # 138 and will showcase its full service capabilities and unique global infrastructure that optimizes Innovative Therapeutics, Generics and 505(b)(2) Programs.

"bioRASI has developed into a powerful full service global CRO that is specifically focused on ANDA, 505(b)(2) NDA and the Translational Stage of Innovative Therapeutics programs," said Dr. Boris Reznik, Chairman of bioRASI. "Our Indian operations joined our very formidable North American and Eastern European operations, and with our greater involvement in South America, we now have a tremendous range of capabilities to help us optimize the cost and time of clinical development programs for our sponsors."

Through its Innovative and Generics divisions, bioRASI leverages its in-depth knowledge and global resources to provide a full range of services to its sponsors, including program management, regulatory strategy design and implementation, clinical development, analytical lab services, Part 11 compliant data management, data analysis and report writing.

bioRASI has leveraged its unique global access to strong PIs and special patient populations to optimize translational clinical development programs. Additionally, utilizing bioRASI's Phase I clinics and bioanalytical laboratories, bioRASI has a rich history of completing difficult to recruit and difficult to perform PK, BE and BA studies.

"As the Translational Clinical Development CRO, we can advance candidates from IND enablement through Proof of Concept, Phase II trials, expeditiously and cost effectively," said Gary W. Thompson, bioRASI's Vice President of Business Development. "With access to thousands of subjects in a number of categories, we have become leaders in difficult to recruit, difficult to perform innovative therapeutics studies."

About bioRASI

bioRASI is a Full Service Global CRO that collaborates with the leading biotech and pharmaceutical companies in the clinical development of novel and generic therapeutics. Specializing in Innovative, ANDA and 505(b)(2) NDA programs, bioRASI facilitates obtaining FDA approvals by delivering high quality regulatory and clinical strategies, solutions and services, while saving their clients critical time. bioRASI services include program management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI leverages its access to world renowned researchers and facilities in the U.S., Europe and Asia, to achieve unparalleled scientific, clinical and business results at significantly lower costs. bioRASI is headquartered in Hollywood, FL and has regional offices, labs, and clinics across the globe.

Lindsey Hall
(786) 388-0700
Email Contact

Read at

comments powered by Disqus